Contact UsQuotation
Shopping Cart
Remove All
  • TargetMol
    Your shopping cart is currently empty
Proceed to checkoutContinue shopping
TOPBioactivityChemical infoStorage&SolubilityCalculator

TLR7/8 agonist 13

🥰Excellent
Catalog No. T212528Cas No. 1402802-45-2

TLR7/8 agonist 13 is an orally active dual agonist of TLR7 (with a lowest effective concentration (LEC) [hTLR7] of 1.6 μM) and TLR8 (LEC [hTLR8] of 1.6 μM). It acts on human peripheral blood mononuclear cells (hPBMC) with agonistic activity (LEC [hPBMC] = 0.5 μM). In mice and cynomolgus monkeys, TLR7/8 agonist 13 induces endogenous IFNα, activates myeloid dendritic cells and monocytes, promoting their differentiation towards a TH1 phenotype. In chronic AAV-HBV mouse models, it reduces viral load and HBV surface antigen levels. TLR7/8 agonist 13 has the potential to indirectly induce IFNγ, facilitating the response of HBV antigen-specific CD8 T cells. This compound is useful for hepatitis B virus research.

TLR7/8 agonist 13

TLR7/8 agonist 13

🥰Excellent
Catalog No. T212528Cas No. 1402802-45-2
TLR7/8 agonist 13 is an orally active dual agonist of TLR7 (with a lowest effective concentration (LEC) [hTLR7] of 1.6 μM) and TLR8 (LEC [hTLR8] of 1.6 μM). It acts on human peripheral blood mononuclear cells (hPBMC) with agonistic activity (LEC [hPBMC] = 0.5 μM). In mice and cynomolgus monkeys, TLR7/8 agonist 13 induces endogenous IFNα, activates myeloid dendritic cells and monocytes, promoting their differentiation towards a TH1 phenotype. In chronic AAV-HBV mouse models, it reduces viral load and HBV surface antigen levels. TLR7/8 agonist 13 has the potential to indirectly induce IFNγ, facilitating the response of HBV antigen-specific CD8 T cells. This compound is useful for hepatitis B virus research.
TargetMol
Product information is being updated, if you want to purchase, please click the bulk custom button.
Add to Quotation
Questions
TargetMol
View More

Resource Download

Product Introduction

Bioactivity
Description
TLR7/8 agonist 13 is an orally active dual agonist of TLR7 (with a lowest effective concentration (LEC) [hTLR7] of 1.6 μM) and TLR8 (LEC [hTLR8] of 1.6 μM). It acts on human peripheral blood mononuclear cells (hPBMC) with agonistic activity (LEC [hPBMC] = 0.5 μM). In mice and cynomolgus monkeys, TLR7/8 agonist 13 induces endogenous IFNα, activates myeloid dendritic cells and monocytes, promoting their differentiation towards a TH1 phenotype. In chronic AAV-HBV mouse models, it reduces viral load and HBV surface antigen levels. TLR7/8 agonist 13 has the potential to indirectly induce IFNγ, facilitating the response of HBV antigen-specific CD8 T cells. This compound is useful for hepatitis B virus research.
In vitro
TLR7/8 agonist 13 (Compound 50 d) stimulates PBMCs to produce IFNα, IFNγ, IL-12p40, IL-12p70, and TNF-α.
In vivo
In a C57Bl/6 mouse model, TLR7/8 agonist 13 (Compound 50 d) (1-50 mg/kg, oral, single dose) induces the response of IFNα, TH1, and myeloid cells. Administered at 5 mg/kg orally once a week for 8 weeks, it inhibits the secretion of HBsAg and reduces HBV viral load through two non-cytotoxic mechanisms in the AAV-HBV C57Bl/6 mouse model. In crab-eating macaques, TLR7/8 agonist 13 (3-30 mg/kg, oral, single dose) stimulates endogenous IFNα production and activates myeloid dendritic cells and monocytes, promoting their development into a TH1 phenotype.
Chemical Properties
Molecular Weight254.33
FormulaC12H22N4O2
Cas No.1402802-45-2
Storage & Solubility Information
StoragePowder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
TargetMol | Animal experimentsFor example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . TargetMol | Animal experiments A total of 10 animals were administered, and the formula you used is 5% TargetMol | reagent DMSO+30% PEG300+5% Tween 80+60% Saline/PBS/ddH2O. So your working solution concentration is 2 mg/mL。
Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSOTargetMol | reagent (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
Preparation method for in vivo formula: Take 50 μL DMSOTargetMol | reagent main solution, add 300 μLPEG300TargetMol | reagent mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLSaline/PBS/ddH2OTargetMol | reagent mix well and clarify
For Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
All types of co-solvents required for the protocol, such asDMSO, PEG300/ PEG400, Tween 80, SBE-β-CD, corn oil are available for purchase on the TargetMol website with a simple click.
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
% Tween 80
% Saline/PBS/ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Related Tags: buy TLR7/8 agonist 13 | purchase TLR7/8 agonist 13 | TLR7/8 agonist 13 cost | order TLR7/8 agonist 13 | TLR7/8 agonist 13 chemical structure | TLR7/8 agonist 13 in vivo | TLR7/8 agonist 13 in vitro | TLR7/8 agonist 13 formula | TLR7/8 agonist 13 molecular weight
TargetMol | Logo

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.